Distribution and marketing of drugs in the UK (England and Wales): overview | Practical Law

Distribution and marketing of drugs in the UK (England and Wales): overview | Practical Law

A Q&A guide to distribution and marketing of drugs law in England and Wales.

Distribution and marketing of drugs in the UK (England and Wales): overview

Practical Law Country Q&A 2-618-6661 (Approx. 19 pages)

Distribution and marketing of drugs in the UK (England and Wales): overview

by Alison Dennis, Taylor Wessing
Law stated as at 01 Nov 2019England, Wales
A Q&A guide to distribution and marketing of drugs law in England and Wales.
The Q&A gives a high-level overview of distribution and marketing of drugs law, including pre-conditions for distribution; licensing; wholesale distribution; marketing to consumers; marketing to professionals and engagement with patient organisations.
This resource may be affected by Brexit. Please note the law-stated date of the resource, and that it may not incorporate all recent developments. The UK left the EU on 31 January 2020. The transition period ended on 31 December 2020 (see Brexit essentials: Q&As on agreements and operation of UK law: What happened at the end of the transition period?). This Country Q&A will be updated in line with our usual publication schedule following the end of transition (see Guide to assessing legal change after end of post-Brexit transition period and UK law after end of post-Brexit transition period: overview). If you require more specific information, please see Beyond Brexit: the legal implications.